-
1 Comment
HealthCare Global Enterprises Limited is currently in a long term uptrend where the price is trading 38.1% above its 200 day moving average.
From a valuation standpoint, the stock is 58.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
HealthCare Global Enterprises Limited's total revenue sank by 1.5% to $3B since the same quarter in the previous year.
Its net income has dropped by 28.2% to $-292M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.8% to $488M since the same quarter in the previous year.
Based on the above factors, HealthCare Global Enterprises Limited gets an overall score of 2/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| ISIN | INE075I01017 |
| PE Ratio | 251.0 |
|---|---|
| Target Price | 692.7143 |
| Beta | -0.12 |
| Market Cap | 92B |
| Dividend Yield | None |
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HCG.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
